LydiaRx
Governance

Governance built as an institution.

Trust, not sequencing capacity, is what constrains national genomics. Our answer is oversight that is independent, nationally led, technically enforced and published.

The Charter

The Sovereignty and Trust Charter.

These are the commitments LydiaRx makes in every programme it works in. Each is enforced technically, institutionally, or both.

  • No sample leaves the country. Collection, extraction, storage and sequencing occur in-country, with chain of custody logged and auditable.
  • No genomic data leaves the country. Raw signal, alignments and variants live on in-country infrastructure only; analysis comes to the data, and egress controls are enforced and independently attested.
  • Open science on national soil. National reference assets are released open-access from in-country servers: openness without export.
  • Consent you can verify. Tiered, broad consent in the languages participants speak; withdrawal honoured through revocation-by-verification, technically enforced and independently checkable.
  • Nationally led oversight. A national-majority Data Access Committee decides every use of the data, with ethics approval before the first participant.
  • Independent audit, published. Third-party audit of consent, custody and access, with summaries published.
  • Benefit stays home. Discoveries from demonstration phases are available royalty-free to the national health system; the national reference is a national good.

Governance documents are drafted to CIOMS, Declaration of Helsinki, UNESCO and GA4GH standards.

Who decides what

Three bodies, three jobs.

01

The Data Access Committee

National majority. Decides every use of the data.

02

The Governance and Ethics Board

Oversees the governance standard, the audit programme and the ethics pathway.

03

LydiaRx

Builds and operates the platform that enforces those decisions. It does not decide access.

Governance and Ethics Board

Who oversees the programme.

  • Dr Andrew RoddamChair

    Former Chief Executive of Our Future Health, the UK's largest health-research programme, built from a standing start to national scale. Oxford DPhil statistician; Chair of SNOMED International.

  • Prof. Kathleen BarnesScientific Committee Chair

    Director, Colorado Center for Personalized Medicine; led its 450,000-patient sequencing partnership with Regeneron. An authority on equitable genomics in non-European ancestry populations.

  • Dr Shahid HanifHealth Data and Pharma Commercial Adviser

    Managing Director, GetReal Institute; formerly Head of Health Data and Outcomes at the ABPI.

  • Dr Imran KausarRegulatory and Therapeutic Adviser

    United Kingdom pharmaceutical physician, with former roles at Sobi, Novartis Gene Therapies and Akcea.

  • National membersEach programme country

    Plus at least 2 nationally based board members will be selected for each country a programme is running in.

The full team and advisers →

Want to see the governance documents?

The Charter, the consent model and the data-access rules are available to governments and ethics committees on request.